Evolution Capital Management
EFTRW icon

Evolution Capital Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Evolution Capital Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$8.18K Hold
50,000
– – 0.03% 43
2022
Q3 		$10K Hold
50,000
– – 0.01% 53
2022
Q2 		$13K Buy
+50,000
New +$13.6K 0.02% 49

Other funds holding EFTRW

Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Whitebox Advisors
Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 13.87% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Tenor Capital Management
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
Parallel Advisors
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
III Capital Management
III Capital Management Boca Raton, Florida $394M AUM 19.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Evolution Capital Management's EFTRW Position: Q4 2022 in Review

Evolution Capital Management held its eFFECTOR Therapeutics, Inc. Warrant (EFTRW) position steady in Q4 2022 at 50,000 shares worth $8.18K. The position accounts for 0.03% of the portfolio, ranked #43.

Evolution Capital Management first reported a position in EFTRW in Q2 2022 and has held it in 3 quarters since. The position peaked at $13K in Q2 2022. 12 funds tracked by Wall St. Rank hold EFTRW as of Q4 2022.

  • Evolution Capital Management held 50,000 shares of eFFECTOR Therapeutics, Inc. Warrant worth $8.18K as of Q4 2022.
  • Evolution Capital Management left its eFFECTOR Therapeutics, Inc. Warrant share count unchanged in Q4 2022.
  • eFFECTOR Therapeutics, Inc. Warrant made up 0.03% of Evolution Capital Management's portfolio in Q4 2022, its #43 holding.
  • Evolution Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2022 and has held it in 3 quarters since.
  • Evolution Capital Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $13K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q4 2022.

Based on Evolution Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.